Prospective Evaluation of the Tecnis Symfony Intraocular Lens (IOL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03579368|
Recruitment Status : Unknown
Verified June 2018 by Kovach Eye Institute.
Recruitment status was: Not yet recruiting
First Posted : July 6, 2018
Last Update Posted : July 6, 2018
Advances in cataract surgery and premium IOLs have allowed the ophthalmologist and optometrist to embrace the fact, as with Lasik patients, that refractive cataract surgery can allow their patients to be potentially free or less dependent on glasses. However, fewer than 13% of all patients undergoing cataract surgery today choose a premium IOL and of these approximately 5% are presbyopic IOLs.
The need for greater optometric involvement in cataract surgery is necessary as demand for cataract surgery increases with the population ageing. According to a recent American Optometric Association survey, optometrists diagnose, on average, 13 cases of cataracts per month and refer or co-manage about half of them that are sent for surgery. Since patients base their decision and selection primarily on doctor recommendations, it is incumbent on the optometric community to be well informed on the benefits of the Advanced Technology IOLs.
There is currently no data that has been collected comparing Advanced Technology IOLs and their clinical outcome and acceptance rate among patients co-managed with optometrists. This pilot study will study the subjective visual symptoms, spectacle independence at various distances and patient satisfaction after bilateral implantation of the Tecnis Symfony Extended Range of Vision Advanced Technology IOL in this co-managed care environment. The primary assessment tool will be a Non-directed Patient Satisfaction and Symptoms Questionnaire. Initial questions would include; "How satisfied are you with your spectacle-free vision at distance/intermediate/near?", "Would you choose the same lens again?" and "Would you recommend the same lens to your relatives and friends". Similarly, with regard to Photic phenomena / visual symptoms, we would ask "Do you experience any problems with your vision?" and only follow up with specific questions on severity once the patient volunteers a specific symptom..
The surgery form will include a question determining the surgeon's satisfaction with the individual Symfony lens implantation. At last visit the optometric investigator will be asked about his satisfaction with the performance of the Symfony lens. This will allow monitoring of any progression of satisfaction as more experience with the lens is obtained.
|Condition or disease||Intervention/treatment||Phase|
|Cataract Cataract Senile||Device: Symfony implantation||Not Applicable|
Symfony Extended Range of Vision IOL was approved by the FDA for commercial use in the United States in August 2016 demonstrating reasonable assurance of safety and effectiveness (PMA # P980040 S065). The Symfony IOL diffracts light in a way that allows an extended range of focus, rather than focusing light at distinct points. Monofocal IOLs have one distinct focus, which can be set by the surgeon for distance, intermediate, or near. Multifocal IOLs have two distinct foci for light, at distance and intermediate or near. The proposed optics of the Symfony are geared toward elongating the eye's focus, rather than producing two distinct focal points. This elongated focus allows a more continuous spectrum of sharp vision from distance through intermediate and to near points. Additionally, because light is not focused at two distinct points, glare and halos should not be as noticeable.
The Symfony IOL offers many advantages to patients, including the absence of a blurry zone of vision between two distinct focal points. With this comes the possibility of reduced glare and halos. Additionally, the extended depth of focus, which is more consistent with accommodating lenses, is not dependent on postoperative movement of the IOL.
An important consideration when selecting this lens is the patient's desired quality of near vision. The defocus curve of the Symfony lens shows vision between 20/15 and 20/20 from distance to approximately 66 cm (2 ft). Vision ranges from 20/20 to 20/30 in the intermediate range of vision until about 50 cm (19 in) and then drops to 20/40 at 40 cm (1 ft). For patients looking for crisp vision for close reading, this lens may not meet expectations.
This study will simply involve following patients who are implanted with the Tecnis Symfony Extended Range of Vision IOL. No clinical testing will be performed on the patients other than those routinely performed by the examining clinician. The only non-routine aspect to the study is the administration of questionnaires to evaluate symptoms and satisfaction. Thus it appears that this study introduces no extra risk to the patient over and above that of the underlying cataract surgery.
The objectives of this single surgical site clinical study are to study the subjective visual symptoms, spectacle independence at various distances and patient satisfaction after bilateral implantation of the Tecnis Symfony Extended Range of Vision IOL in a co-managed care environment (Ophthalmologists and Optometrists).
The patient population for this clinical study will be 200 bilaterally implanted Symfony IOL patients from 10 optometric practices who fit the inclusion/exclusion criteria for this study determined at 1 month postoperatively and were referred to a single surgical site.
This study will be a prospective clinical investigation. The study endpoint will be at 3 months postoperatively. Subjects will be recruited from the referring optometrist's current patient population. Subjects will be enrolled into the study in a sequential manner only after it has been determined that they are qualified according to the Clinical Protocol inclusion and exclusion criteria. The study will involve a single surgical site (Principal Investigator and Surgeon Co-Investigator) and 10 co-managing optometric referring sites (Co-Investigators). Informed consent, testing study subject questionnaire administration will be conducted at the co-managing optometric sites. Surgery will be performed at the single surgical site.
The incidence of subjective visual symptoms, spectacle independence at various distances and patient satisfaction will be tabulated for each center and for the population as a whole
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Single group study|
|Masking:||None (Open Label)|
|Official Title:||A Prospective Evaluation of the Tecnis Symfony Extended Range of Vision Presbyopia Correcting IOL|
|Estimated Study Start Date :||July 5, 2018|
|Estimated Primary Completion Date :||April 15, 2019|
|Estimated Study Completion Date :||May 15, 2019|
Patients undergoing bilateral IOL implantation with the Tecnis Symfony Extended Range of Vision IOL at a single surgical site
Device: Symfony implantation
Bilateral Symfony IOL Implantation
- Patient satisfaction & Spectacle independence [ Time Frame: 3 months postoperatively ]Patient questionaire
- Patient satisfaction & Spectacle independence [ Time Frame: 1 month postoperatively ]Patient questionaire
- Surgeon Satisfaction [ Time Frame: Intraoperative ]Satisfaction questionaire
- Referring Optometrist Satisfaction [ Time Frame: 3 months postoperatively ]Satisfaction questionaire
- Patient Symptoms [ Time Frame: 1 month postoperative ]Symptom Questionaire
- Patient Symptoms [ Time Frame: 3 months postoperative ]Symptom Questionaire
- Adverse Events and Complications [ Time Frame: 1 month postoperative ]Adverse Events and Complications
- Adverse Events and Complications [ Time Frame: 3 months postoperative ]Adverse Events and Complications
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03579368
|Contact: Donald R Sanders, MD. PhDemail@example.com|
|Contact: Wes Becton||630-833-9621 ext firstname.lastname@example.org|
|Study Director:||Donald R Sanders||Center for Clinical Research|